Statements (51)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antipsychotic medication
phenothiazine derivative |
| gptkbp:administeredBy |
animals
humans |
| gptkbp:ATCCode |
N05AA01
|
| gptkbp:brand |
gptkb:Largactil
gptkb:Thorazine |
| gptkbp:CASNumber |
50-53-3
|
| gptkbp:contraindication |
gptkb:pheochromocytoma
bone marrow depression severe CNS depression hypersensitivity to phenothiazines |
| gptkbp:discoveredBy |
gptkb:Paul_Charpentier
|
| gptkbp:discoveredIn |
1950
|
| gptkbp:drugClass |
neuroleptic
typical antipsychotic |
| gptkbp:eliminationHalfLife |
30 hours
|
| gptkbp:excretion |
urine
bile |
| gptkbp:hasMolecularFormula |
C17H19ClN2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
Chlorpromazine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
1953
|
| gptkbp:mechanismOfAction |
dopamine D2 receptor antagonist
antagonist at histamine, muscarinic, and alpha-adrenergic receptors |
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
weight gain
hypotension sedation photosensitivity extrapyramidal symptoms neuroleptic malignant syndrome tardive dyskinesia anticholinergic effects |
| gptkbp:synonym |
gptkb:CPZ
Chlorpromazin |
| gptkbp:usedFor |
gptkb:acute_intermittent_porphyria
nausea schizophrenia vomiting psychotic disorders intractable hiccups preoperative sedation manic phases of bipolar disorder |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Parke-Davis
|
| gptkbp:bfsLayer |
7
|